Table 3 Nicotine vaping product prevalence (%), validation for US SAVM against NHIS by age and gender in the year 2018
From: Public health implications of vaping in the USA: the smoking and vaping simulation model
Ages | 18+ | 18–24 | 25–44 | 45–64 | 65+ |
|---|---|---|---|---|---|
US males | |||||
 SAVM | 3.0 | 7.5 | 4.2 | 1.4 | 0.5 |
 NHIS | 3.1 | 6.8 | 4.7 | 1.5 | 0.6 |
 NHIS 95% CI | 2.7–3.5 | 4.8–8.8 | 3.8–5.6 | 1.0–1.9 | 0.3–0.9 |
US females | |||||
 SAVM | 1.8 | 4.9 | 2.4 | 1.0 | 0.4 |
 NHIS | 1.5 | 3.1 | 1.9 | 1.3 | 0.5 |
 NHIS 95% CI | 1.3–1.8 | 1.8–4.5 | 1.4–2.3 | 1.0–1.7 | 0.3–0.7 |